VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
VERACYTE, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$43.80+0.68 (+1.58%)
Close on Oct 19, 2026
- Market cap
- $3.59B
- P/E (TTM)
- 31.3
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
89M of 80M shares
Institutional holders
370
80 new, 41 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 57 sales
Net sold $21.03M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC | 8,059,903 | 10.10% | 13G (passive) amendment | May 29, 2026 |
| Abigail P. Johnson | 6,735,697 | 8.60% | 13G (passive) amendment | Sep 30, 2025 |
| Artisan Investments GP LLC | 6,263,041 | 7.90% | 13G (passive) amendment | Dec 31, 2025 |
| Artisan Partners Limited Partnership | 5,496,370 | 6.90% | 13G (passive) amendment | Mar 31, 2026 |
| Artisan Partners Asset Management Inc. | 5,239,711 | 6.70% | 13G (passive) amendment | Mar 31, 2025 |
| State Street Corporation | 5,043,590 | 6.30% | 13G (passive) | Mar 31, 2026 |
| Vanguard Portfolio Management | 4,512,852 | 5.67% | 13G (passive) | Mar 31, 2026 |
| Catherine D. Wood | 4,465,775 | 5.68% | 13G (passive) | Sep 30, 2025 |
| Vanguard Capital Management | 4,132,224 | 5.20% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 11,930,018 | 15.20% | 13G (passive) amendment | Jul 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VCYT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,486,437 | 16.78% | $792.06M | +313,819 | 0.01% |
| FMR LLC | 7,702,746 | 9.58% | $452.38M | −61,103 | 0.02% |
| Artisan Partners Limited Partnership | 5,538,404 | 6.89% | $325.27M | +42,034 | 0.52% |
| Vanguard Portfolio Management LLC | 4,716,191 | 5.87% | $276.98M | +271,461 | 0.01% |
| State Street Corp | 4,698,128 | 5.84% | $275.95M | −345,462 | 0.01% |
| Vanguard Capital Management LLC | 3,593,922 | 4.47% | $211.07M | +61,690 | 0.00% |
| Dimensional Fund Advisors LP | 2,826,524 | 3.52% | $166.01M | −54,566 | 0.03% |
| First Trust Advisors LP | 2,507,902 | 3.12% | $147.29M | +390,856 | 0.09% |
| ARK Investment Management LLC | 2,295,951 | 2.86% | $134.84M | −757,867 | 0.88% |
| Wellington Management Group Llp | 2,274,160 | 2.83% | $133.56M | −284,125 | 0.02% |
| Geode Capital Management, LLC | 2,104,000 | 2.62% | $123.59M | +146,904 | 0.01% |
| Goldman Sachs Group Inc | 1,642,911 | 2.04% | $96.49M | +366,651 | 0.01% |
| Fuller & Thaler Asset Management, Inc. | 1,509,749 | 1.88% | $88.67M | +95,387 | 0.24% |
| William Blair Investment Management, LLC | 1,431,596 | 1.78% | $84.08M | +441,909 | 0.25% |
| GW&K Investment Management, LLC | 1,416,543 | 1.76% | $83.19K | −20,779 | 0.65% |
| Morgan Stanley | 1,191,790 | 1.48% | $69.99M | +393,988 | 0.00% |
| Bank Of America Corp /De/ | 1,102,279 | 1.37% | $64.74M | −346,618 | 0.00% |
| Driehaus Capital Management LLC | 1,045,826 | 1.30% | $61.42M | New | 0.36% |
| Northern Trust Corp | 996,154 | 1.24% | $58.50M | +66,654 | 0.01% |
| Charles Schwab Investment Management Inc | 939,983 | 1.17% | $55.21M | +16,410 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 370 | 89M | 100.0% | 80 / 128 | 122 / 41 | 9M | 8M |
| Q1 2026 | 334 | 88M | 100.0% | 48 / 142 | 102 / 37 | 18M | 8M |
| Q4 2025 | 329 | 88M | 100.0% | 65 / 108 | 115 / 28 | 8M | 10M |
| Q3 2025 | 298 | 90M | 100.0% | 70 / 95 | 90 / 46 | 17M | 12M |
| Q2 2025 | 278 | 85M | 100.0% | 36 / 102 | 103 / 43 | 10M | 9M |
| Q1 2025 | 287 | 85M | 100.0% | 27 / 112 | 107 / 56 | 12M | 8M |
| Q4 2024 | 318 | 82M | 100.0% | 54 / 105 | 121 / 25 | 11M | 11M |
| Q3 2024 | 293 | 82M | 100.0% | 77 / 87 | 91 / 22 | 19M | 11M |
| Q2 2024 | 240 | 83M | 100.0% | 26 / 90 | 85 / 29 | 7M | 7M |
| Q1 2024 | 246 | 83M | 100.0% | 35 / 118 | 66 / 37 | 9M | 4M |
| Q4 2023 | 250 | 78M | 97.0% | 35 / 80 | 105 / 20 | 5M | 4M |
| Q3 2023 | 236 | 77M | 95.3% | 28 / 97 | 79 / 20 | 5M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of VCYT | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 4,807,245 | 5.98% | $282.33M | 0.25% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,532,110 | 3.15% | $148.71M | 0.01% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 2,441,185 | 3.04% | $143.37M | 5.10% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,079,919 | 2.59% | $122.15M | 0.15% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,830,642 | 2.28% | $107.51M | 0.06% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,496,464 | 1.86% | $87.89M | 0.82% | Jun 30, 2026 |
| Select Health Care Portfolio | 1,280,000 | 1.59% | $59.32M | 1.03% | May 31, 2026 |
| Artisan Mid Cap Fund | 1,236,133 | 1.54% | $72.60M | 2.27% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,053,887 | 1.31% | $61.89M | 0.13% | Jun 30, 2026 |
| ARK Innovation ETF | 1,026,015 | 1.28% | $47.53M | 0.85% | Jul 31, 2026 |
| Select Medical Technology and Devices Portfolio | 1,000,000 | 1.24% | $46.34M | 1.56% | May 31, 2026 |
| Vanguard Explorer Fund | 983,816 | 1.22% | $45.57M | 0.21% | Jul 31, 2026 |
| Fullerthaler Behavioral Small-Cap Growth | 977,500 | 1.22% | $57.41M | 0.93% | Jun 30, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 956,773 | 1.19% | $56.19M | 0.50% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 915,041 | 1.14% | $53.74M | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Marc Stapley | Chief Executive Officer, Director | 432,073 | 0.54% | Sep 4, 2026 |
| John Leite | Global Chief Commercial Off | 124,329 | 0.15% | Sep 22, 2026 |
| Rebecca Chambers | Chief Financial Officer | 167,200 | 0.21% | Sep 4, 2026 |
| Jonathan Wygant | VP, Chief Accounting Officer | 43,226 | 0.05% | Sep 4, 2026 |
| Annie McGuire | EVP, General Counsel | 132,260 | 0.16% | Sep 4, 2026 |
| Phillip G. Febbo | Chief Scientific & Med Officer | 133,048 | 0.17% | Sep 4, 2026 |
| Kevin Richard Haas | Chief Dev and Tech Officer | 44,221 | 0.06% | Apr 14, 2026 |
| Jens Holstein | Director | 27,471 | 0.03% | Sep 16, 2026 |
| Muna Bhanji | Director | 42,718 | 0.05% | Sep 3, 2026 |
| Karin Eastham | Director | 16,338 | 0.02% | Jun 22, 2026 |
| Evan/ Fa Jones | Director | 34,634 | 0.04% | Jun 15, 2026 |
| Robert S. Epstein | Director | 57,718 | 0.07% | Jun 15, 2026 |
| David Brent Shafer | Director | 31,100 | 0.04% | Jun 15, 2026 |
| Eliav Barr | Director | 56,461 | 0.07% | Jun 15, 2026 |
| Thomas F. Miller | Director | 31,100 | 0.04% | Jun 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John Leite Global Chief Commercial Off | Sep 21, 2026 | Sale(10b5-1 plan) | −4,015 | $40.00 | $160.60K | 124,329 |
| Jens Holstein Director | Sep 14, 2026 | Sale(10b5-1 plan) | −5,000 | $40.95 | $204.75K | 27,471 |
| Phillip G. Febbo Chief Scientific & Med Officer | Sep 4, 2026 | Sale(10b5-1 plan) | −2,705 | $43.66 | $118.10K | 133,048 |
| Phillip G. Febbo Chief Scientific & Med Officer | Sep 4, 2026 | Sale(10b5-1 plan) | −10,405 | $42.89 | $446.27K | 135,753 |
| Annie McGuire EVP, General Counsel | Sep 4, 2026 | Sale(10b5-1 plan) | −2,154 | $42.79 | $92.17K | 132,260 |
| Annie McGuire EVP, General Counsel | Sep 4, 2026 | Sale(10b5-1 plan) | −1,100 | $43.67 | $48.04K | 131,160 |
| Rebecca Chambers Chief Financial Officer | Sep 4, 2026 | Sale(10b5-1 plan) | −2,477 | $42.81 | $106.04K | 167,200 |
| Rebecca Chambers Chief Financial Officer | Sep 4, 2026 | Sale(10b5-1 plan) | −1,175 | $43.71 | $51.36K | 166,025 |
| Phillip G. Febbo Chief Scientific & Med Officer | Sep 2, 2026 | Tax withholding | −3,639 | $44.88 | $163.32K | 146,158 |
| John Leite Global Chief Commercial Off | Sep 2, 2026 | Tax withholding | −3,961 | $44.88 | $177.77K | 128,344 |
| Annie McGuire EVP, General Counsel | Sep 2, 2026 | Tax withholding | −3,215 | $44.88 | $144.29K | 134,414 |
| Rebecca Chambers Chief Financial Officer | Sep 2, 2026 | Tax withholding | −3,603 | $44.88 | $161.70K | 169,677 |
| Marc Stapley Chief Executive Officer, Director | Sep 2, 2026 | Tax withholding | −8,782 | $44.88 | $394.14K | 432,073 |
| Jonathan Wygant VP, Chief Accounting Officer | Sep 2, 2026 | Tax withholding | −1,361 | $44.88 | $61.08K | 43,226 |
| Muna Bhanji Director | Sep 1, 2026 | Sale(10b5-1 plan) | −1,864 | $42.97 | $80.10K | 42,718 |
| Karin Eastham Director | Jun 18, 2026 | Sale(10b5-1 plan) | −529 | $53.55 | $28.33K | 15,097 |
| Karin Eastham Director | Jun 18, 2026 | Sale(10b5-1 plan) | −3,200 | $52.78 | $168.90K | 15,626 |
| Jens Holstein Director | Jun 11, 2026 | Award | +5,272 | – | – | 32,471 |
| Karin Eastham Director | Jun 11, 2026 | Award | +5,272 | – | – | 18,826 |
| Evan/ Fa Jones Director | Jun 11, 2026 | Award | +5,272 | – | – | 34,634 |
| Thomas F. Miller Director | Jun 11, 2026 | Award | +5,272 | – | – | 31,100 |
| Robert S. Epstein Director | Jun 11, 2026 | Award | +5,272 | – | – | 57,718 |
| Eliav Barr Director | Jun 11, 2026 | Award | +5,272 | – | – | 56,461 |
| Muna Bhanji Director | Jun 11, 2026 | Award | +5,272 | – | – | 44,582 |
| David Brent Shafer Director | Jun 11, 2026 | Award | +5,272 | – | – | 31,100 |
| John Leite Global Chief Commercial Off | Jun 4, 2026 | Sale(10b5-1 plan) | −13,975 | $50.07 | $699.73K | 132,305 |
| Rebecca Chambers Chief Financial Officer | Jun 4, 2026 | Sale(10b5-1 plan) | −1,961 | $50.09 | $98.23K | 173,280 |
| Rebecca Chambers Chief Financial Officer | Jun 4, 2026 | Sale(10b5-1 plan) | −1,600 | $49.28 | $78.85K | 175,241 |
| Marc Stapley Chief Executive Officer, Director | Jun 4, 2026 | Sale(10b5-1 plan) | −138,051 | $50.12 | $6.92M | 440,494 |
| Marc Stapley Chief Executive Officer, Director | Jun 4, 2026 | Option exercise | +138,051 | $36.60 | $5.05M | 578,545 |
| Annie McGuire EVP, General Counsel | Jun 4, 2026 | Sale(10b5-1 plan) | −1,400 | $49.31 | $69.03K | 139,016 |
| Annie McGuire EVP, General Counsel | Jun 4, 2026 | Sale(10b5-1 plan) | −1,776 | $50.12 | $89.01K | 137,240 |
| John Leite Global Chief Commercial Off | Jun 2, 2026 | Tax withholding | −4,059 | $47.80 | $194.02K | 146,280 |
| Rebecca Chambers Chief Financial Officer | Jun 2, 2026 | Tax withholding | −3,693 | $47.80 | $176.53K | 176,841 |
| Phillip G. Febbo Chief Scientific & Med Officer | Jun 2, 2026 | Tax withholding | −3,730 | $47.80 | $178.29K | 149,797 |
| Jonathan Wygant VP, Chief Accounting Officer | Jun 2, 2026 | Tax withholding | −1,361 | $47.80 | $65.06K | 44,073 |
| Marc Stapley Chief Executive Officer, Director | Jun 2, 2026 | Tax withholding | −9,012 | $47.80 | $430.77K | 440,494 |
| Annie McGuire EVP, General Counsel | Jun 2, 2026 | Tax withholding | −3,292 | $47.80 | $157.36K | 140,416 |
| Jonathan Wygant VP, Chief Accounting Officer | May 22, 2026 | Sale | −24,000 | $45.40 | $1.09M | 45,434 |
| Jonathan Wygant VP, Chief Accounting Officer | May 22, 2026 | Option exercise | +24,000 | $24.80 | $595.20K | 69,434 |
| Robert S. Epstein Director | May 20, 2026 | Sale(10b5-1 plan) | −10,000 | $44.01 | $440.10K | 52,446 |
| Annie McGuire SVP, General Counsel | May 6, 2026 | Sale(10b5-1 plan) | −5,102 | $40.00 | $204.08K | 143,708 |
| Annie McGuire SVP, General Counsel | May 6, 2026 | Sale(10b5-1 plan) | −5,102 | $38.05 | $194.13K | 148,810 |
| Kevin Richard Haas Chief Dev and Tech Officer | Apr 10, 2026 | Award | +44,221 | – | – | 44,221 |
| Rebecca Chambers Chief Financial Officer | Mar 6, 2026 | Award | +13,157 | – | – | 180,534 |
| Rebecca Chambers Chief Financial Officer | Mar 6, 2026 | Award | +36,181 | – | – | 167,377 |
| Annie McGuire SVP, General Counsel | Mar 6, 2026 | Award | +26,314 | – | – | 153,912 |
| Annie McGuire SVP, General Counsel | Mar 6, 2026 | Award | +32,892 | – | – | 127,598 |
| Marc Stapley Chief Executive Officer, Director | Mar 6, 2026 | Award | +92,099 | – | – | 449,653 |
| Jonathan Wygant VP, Chief Accounting Officer | Mar 6, 2026 | Award | +10,525 | – | – | 45,434 |
| Phillip G. Febbo Chief Scientific & Med Officer | Mar 6, 2026 | Award | +29,603 | – | – | 146,949 |
| Phillip G. Febbo Chief Scientific & Med Officer | Mar 6, 2026 | Award | +6,578 | – | – | 153,527 |
| John Leite Chief Commercial Officer-CLIA | Mar 6, 2026 | Award | +36,181 | – | – | 143,761 |
| John Leite Chief Commercial Officer-CLIA | Mar 6, 2026 | Award | +6,578 | – | – | 150,339 |
| Annie McGuire SVP, General Counsel | Mar 4, 2026 | Sale(10b5-1 plan) | −1,664 | $36.34 | $60.47K | 94,706 |
| Annie McGuire SVP, General Counsel | Mar 4, 2026 | Sale(10b5-1 plan) | −4,994 | $35.29 | $176.24K | 96,370 |
| Rebecca Chambers Chief Financial Officer | Mar 4, 2026 | Sale(10b5-1 plan) | −4,400 | $35.55 | $156.42K | 145,137 |
| Rebecca Chambers Chief Financial Officer | Mar 4, 2026 | Sale(10b5-1 plan) | −13,941 | $36.33 | $506.48K | 131,196 |
| John Leite Chief Commercial Officer-CLIA | Mar 4, 2026 | Sale(10b5-1 plan) | −5,260 | $35.19 | $185.10K | 107,580 |
| Marc Stapley Chief Executive Officer, Director | Mar 4, 2026 | Sale(10b5-1 plan) | −19,244 | $35.56 | $684.32K | 383,833 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Holstein Jens Director | Sep 24, 2026 | 7,500 | $352.50K | Sep 24, 2026 | Stock Option Exercise |
| Leite John Officer | Sep 21, 2026 | 4,015 | $159.78K | Sep 21, 2026 | Restricted Stock Units |
| Holstein Jens Director | Sep 14, 2026 | 5,000 | $204.75K | Sep 14, 2026 | Restricted Stock |
| McGuire Ann Officer | Sep 4, 2026 | 3,254 | $145.36K | Sep 4, 2026 | Restricted Stock Units |
| Febbo Phillip Officer | Sep 4, 2026 | 13,110 | $585.62K | Sep 4, 2026 | Restricted Stock Units |
| Chambers Rebecca Officer | Sep 4, 2026 | 3,652 | $163.13K | Sep 4, 2026 | Restricted Stock Units |
| Bhanji Muna Director | Sep 1, 2026 | 3,728 | $161.01K | Sep 1, 2026 | Restricted Stock Units |
| Eastham Karin Director | Jun 18, 2026 | 3,729 | $191.26K | Jun 18, 2026 | Restricted Stock Units |
| McGuire Ann Officer | Jun 4, 2026 | 3,176 | $154.64K | Jun 4, 2026 | Restricted Stock Units |
| Leite John Officer | Jun 4, 2026 | 13,975 | $680.44K | Jun 4, 2026 | Restricted Stock Units |
| Stapley Marc Director, Officer | Jun 4, 2026 | 138,051 | $6.72M | Jun 4, 2026 | Exercise of Stock Options |
| Chambers Rebecca Officer | Jun 4, 2026 | 3,561 | $173.39K | Jun 4, 2026 | Restricted Stock Units |
| Epstein Robert Director | May 20, 2026 | 10,000 | $416.90K | May 20, 2026 | Previously Exercised Stock Options |
| McGuire Ann Officer | May 6, 2026 | 10,204 | $336.43K | May 6, 2026 | Performance Stock Units |
| Chambers Rebecca Officer | Mar 4, 2026 | 18,341 | $643.40K | Mar 4, 2026 | Restricted Stock Units |